Consequently, clinical trials are evaluating combination therapies with inhibitors against PI3K and MAPK signaling members, such as PI3K, AKT, mTOR, BRAF, and MEK, which are approved to treat different cancers as monotherapies or in combination with other agents (11, 12, 13). Here, PIK3CA is linked to cancer.